Lenalidomida Sandoz (Lenalidomide)

• Lenalidomide is used in hematologic oncology to target malignant plasma cells and related disease pathways.
• Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients.
• Mantle Cell Lymphoma: contributes to disease control when combined with other agents in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in reduced tumor cell proliferation, inhibition of angiogenesis, and modulation of immune cell activity, including enhanced natural killer cell function and cytokine production. These molecular actions collectively contribute to its antineoplastic efficacy in approved indications.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Neutropenia: decreased neutrophil count, increasing infection risk.
• Thrombocytopenia: reduced platelet levels, may cause bruising.
• Anemia: lowered red blood cell count, leading to fatigue.
• Fatigue: general tiredness and reduced stamina.
• Diarrhea: loose stools, sometimes accompanied by abdominal cramping.
• Rash: mild skin eruptions, often pruritic.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Secondary primary malignancies: emergence of new cancers during therapy.
• Hepatotoxicity: significant elevation of liver enzymes or liver injury.
• Pregnancy‑related teratogenicity: birth defects if exposure occurs during gestation.

• Before initiating Lenalidomida Sandoz, clinicians should observe several precautionary measures to ensure patient safety.
• Monitor blood counts: perform regular complete blood count tests to detect cytopenias.
• Assess renal function: adjust dosing in patients with impaired kidney function.
• Avoid pregnancy: enforce effective contraception due to known teratogenic risk.
• Vaccination considerations: defer live vaccines while on therapy.
• Drug‑specific counseling: inform patients about signs of thromboembolism and skin reactions.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with thrombocytopenia.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels modestly.
• Immunosuppressants (e.g., cyclosporine): may augment immunomodulatory effects.
• Hormonal contraceptives: potential reduced effectiveness, consider additional barrier methods.